Prot #TAK-676-1002: An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastat

Project: Research project

Project Details

StatusActive
Effective start/end date5/21/24 → 5/21/27

Funding

  • Pharmaceutical Research Associates, Inc. (Prot #TAK-676-1002 // Prot #TAK-676-1002)
  • Takeda Development Center Americas, Inc. (Prot #TAK-676-1002 // Prot #TAK-676-1002)